CA2421786A1 - Composes et procedes pour l'inhibition d'integrines alpha-1 beta-1 - Google Patents

Composes et procedes pour l'inhibition d'integrines alpha-1 beta-1 Download PDF

Info

Publication number
CA2421786A1
CA2421786A1 CA002421786A CA2421786A CA2421786A1 CA 2421786 A1 CA2421786 A1 CA 2421786A1 CA 002421786 A CA002421786 A CA 002421786A CA 2421786 A CA2421786 A CA 2421786A CA 2421786 A1 CA2421786 A1 CA 2421786A1
Authority
CA
Canada
Prior art keywords
integrin
xaa
cys
beta
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002421786A
Other languages
English (en)
Inventor
Cezary Marcinkiewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University of Commonwealth System of Higher Education
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2421786A1 publication Critical patent/CA2421786A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne l'obtustatine, une disintégrine courte indéprendante de la séquence RGD (arginine-glycine-acide aspartique), qui a une action inhibitrice puissante et sélective sur la liaison de l'intégrine .alpha.1.beta.1 avec son ligand d'adhésion. On peut utiliser l'obtustatine, y compris ses fragments, dérives, homologues et analogues, pour le traitement des maladies et pour moduler les états biologiques associés à l'intégrine .alpha.1.beta.1.
CA002421786A 2000-09-11 2001-09-12 Composes et procedes pour l'inhibition d'integrines alpha-1 beta-1 Abandoned CA2421786A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23159100P 2000-09-11 2000-09-11
US60/231,591 2000-09-11
PCT/US2001/028522 WO2002022571A2 (fr) 2000-09-11 2001-09-12 Composes et procedes pour l'inhibition d'integrines alpha-1 beta-1

Publications (1)

Publication Number Publication Date
CA2421786A1 true CA2421786A1 (fr) 2002-03-21

Family

ID=22869882

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002421786A Abandoned CA2421786A1 (fr) 2000-09-11 2001-09-12 Composes et procedes pour l'inhibition d'integrines alpha-1 beta-1

Country Status (4)

Country Link
EP (1) EP1322322A4 (fr)
AU (1) AU2001294552A1 (fr)
CA (1) CA2421786A1 (fr)
WO (1) WO2002022571A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016883A2 (fr) * 2003-08-14 2005-02-24 Icos Corporation Derives d'acrylamide servant d'antagonistes de l'integrine vla-1, et leurs utilisations
WO2015087334A1 (fr) 2013-12-15 2015-06-18 Yissum Research Develoment Company Of The Hebrew University Of Jerusalem Ltd. Peptides dérivés de vipéristatine et leurs utilisations
MA49645A (fr) * 2017-07-20 2021-03-31 Univ Virginia Patent Foundation Procédés de traitement ou de prévention d'un trouble neurologique du système immunitaire
CN110974938A (zh) * 2019-12-02 2020-04-10 上海长海医院 整合素α1β1抑制剂在制备预防或治疗主动脉疾病药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors

Also Published As

Publication number Publication date
WO2002022571A3 (fr) 2002-06-20
WO2002022571A2 (fr) 2002-03-21
AU2001294552A1 (en) 2002-03-26
EP1322322A4 (fr) 2005-04-06
EP1322322A2 (fr) 2003-07-02

Similar Documents

Publication Publication Date Title
RU2156468C2 (ru) Способ определения присутствия или отсутствия активности в ингибировании агрегации тромбоцитов (ра1), очищенный и выделенный ингибитор активности тромбоцитов (ра1) и/или укороченная его форма, способ очистки ра1 из змеиного яда, фармацевтическая композиция для предотвращения образования тромба, способ ингибирования образования тромба
US5981478A (en) Integrin-binding peptides
US6177542B1 (en) Integrin-binding peptides
PRECIADO‐PATT et al. Inhibition of cell adhesion to glycoproteins of the extracellular matrix by peptides corresponding to serum amyloid A: toward understanding the physiological role of an enigmatic protein
US5863897A (en) Synducin mediated modulation of tissue repair
US5506208A (en) Method for using synthetic analogs of thrombospondin for inhibiting angiogenesis activity
CA2052022A1 (fr) Peptides ayant une activite semblable a celle de la thrombospondine et leur utilisation a des fins therapeutiques
JP2005272480A (ja) トロンボスポンジン−様活性を有するペプチド及びその治療のための使用
US20010034326A1 (en) Peptide inhibitors of LFA-1/ICAM-1 interaction
US20030186334A1 (en) KTS-disintegrins
CA2421786A1 (fr) Composes et procedes pour l'inhibition d'integrines alpha-1 beta-1
CA2610496A1 (fr) Inhibiteur de thrombine a peptides synthetiques et activation par thrombine des recepteurs actives par les proteases 1 et 4
WO1992020708A1 (fr) Peptides inhibiteurs de l'inflammation
US20080280833A1 (en) Therapeutic Peptides Derived from Urokinase Plasminogen Activator Receptor

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20060912